This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zafon, C. Articles by Simó, R. Search for Related Content PubMed PubMed Citation Articles by Zafon, C. Articles by Simó, R.

nm23-H1 Immunoreactivity as a Prognostic Factor in Differentiated Thyroid Carcinoma

Division of Endocrinology (C.Z., G.O., J.M., R.S.), Department of Pathology (J.C., N.T.), Department of Nuclear Medicine (P.G.), and Unit of Endocrinological Surgery (E.G.), Hospital General i Universitari Vall d’Hebron, Barcelona 08035, Spain

Address all correspondence and requests for reprints to: Rafael Simó, M.D., Division of Endocrinology, Hospital General Vall d’Hebron, Pg. Vall d’Hebron 119–129, 08035 Barcelona, Spain. E-mail: rsimo{at}hg vhebron.es.

Abstract

Several prognostic factors have been proposed to identify the patients at risk to develop metastases in differentiated thyroid carcinoma. Reduced nm23-H1 expression (a metastatic suppressor gene) has been correlated with high tumor metastatic potential in various human carcinomas, but the results obtained in differentiated thyroid carcinoma remain controversial.

To elucidate the usefulness of nm23-H1 as a differentiated thyroid carcinoma prognosis factor, we evaluate the relationship between nm23-H1 immunoreactivity as well as both clinical status and patient outcome. For this purpose, thyroid resected specimens obtained from 94 differentiated thyroid carcinoma consecutive patients (64 papillary and 30 follicular) with at least 5 yr of follow-up were stained using monoclonal antibody to nm23-H1.

We did not observe any relationship between nm23-H1 immunoreactivity and age, gender, initial differentiated thyroid carcinoma stage, local recurrence, or distant metastases in patients with papillary carcinoma. However, in patients with follicular carcinoma, a significant inverse association between metastatic disease and the expression of nm23-H1 product was obtained (P < 0.05). In addition, significant differences were found in the survival curves according to nm23-H1 immunoreactivity (log-rank P < 0.01). Finally, nm-23-H1 immunoreactivity was more specific but less sensitive than AMES score to predict metastases.

In conclusion, our results suggest that nm23-H1 immunostaining could be added to the classic prognostic factors currently used to predict the outcome of patients with follicular thyroid carcinoma.

This article has been cited by other articles:

				R. T. Netea-Maier, S. W. Hunsucker, B. M. Hoevenaars, S. M. Helmke, P. J. Slootweg, A. R. Hermus, B. R. Haugen, and M. W. Duncan Discovery and Validation of Protein Abundance Differences between Follicular Thyroid Neoplasms Cancer Res., March 1, 2008; 68(5): 1572 - 1580. [Abstract] [Full Text] [PDF]